文献速递淋巴瘤

维奈克拉联合奥妥珠单抗治疗初治慢性淋巴细胞白血病:随机III期CLL14研究的6年结果

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
PubMed 文献 · Blood · 2024-01-01

CLL14研究将初治伴合并症的慢性淋巴细胞白血病患者随机分配至12周期维奈克拉-奥妥珠单抗(Ven-Obi,n=216)或苯丁酸氮芥-奥妥珠单抗(Clb-Obi,n=216),中位观察76.4个月时Ven-Obi组无进展生存仍优于Clb-Obi组(中位76.2 vs 36.4个月;HR 0.40;95%CI 0.31-0.52;P<.0001),6年总生存率78.7% vs 69.2%(HR 0.69;95%CI 0.48-1.01;P=.052),全球健康状况/生活质量至确定性恶化时间亦更长(中位82.1 vs 65.1个月;HR 0.70;95%CI 0.51-0.97),支持使用1年固定疗程Ven-Obi。

要点

  • 中位观察76.4个月,Ven-Obi组中位无进展生存76.2个月 vs Clb-Obi组36.4个月(HR 0.40;95%CI 0.31-0.52;P<.0001)。
  • Ven-Obi组6年至下次治疗率65.2% vs Clb-Obi组37.1%(HR 0.44;95%CI 0.33-0.58;P<.0001)。
  • 6年总生存率Ven-Obi组78.7% vs Clb-Obi组69.2%(HR 0.69;95%CI 0.48-1.01;P=.052),未达统计学显著。

核心结论

  • 持续长期生存和生活质量获益支持在慢性淋巴细胞白血病中使用1年固定疗程维奈克拉-奥妥珠单抗。

研究设计与样本

  • CLL14研究为随机III期研究,将初治伴合并症的慢性淋巴细胞白血病患者随机分配至12周期维奈克拉-奥妥珠单抗(Ven-Obi,n=216)或苯丁酸氮芥-奥妥珠单抗(Clb-Obi,n=216),主要终点为无进展生存。

主要发现

  • 中位观察76.4个月时,Ven-Obi组无进展生存仍优于Clb-Obi组(中位76.2 vs 36.4个月;HR 0.40;95%CI 0.31-0.52;P<.0001)。
  • Ven-Obi组至下次治疗时间长于Clb-Obi组(6年时65.2% vs 37.1%;HR 0.44;95%CI 0.33-0.58;P<.0001)。
  • Ven-Obi组中,del(17p)、免疫球蛋白重链可变区未突变和淋巴结大小≥5 cm是较短无进展生存的独立预后因素。
  • 6年总生存率Ven-Obi组78.7% vs Clb-Obi组69.2%(HR 0.69;95%CI 0.48-1.01;P=.052)。
  • 全球健康状况/生活质量至确定性恶化时间Ven-Obi组长于Clb-Obi组(中位82.1 vs 65.1个月;HR 0.70;95%CI 0.51-0.97);随访校正的第二原发恶性肿瘤发生率分别为Ven-Obi组2.3例/1000患者月与Clb-Obi组1.4例/1000患者月。

关键数值与推荐

  • 中位无进展生存:Ven-Obi组76.2个月 vs Clb-Obi组36.4个月(HR 0.40;95%CI 0.31-0.52;P<.0001)。
  • 6年总生存率:Ven-Obi组78.7% vs Clb-Obi组69.2%(HR 0.69;95%CI 0.48-1.01;P=.052)。
  • 6年至下次治疗率:Ven-Obi组65.2% vs Clb-Obi组37.1%(HR 0.44;95%CI 0.33-0.58;P<.0001)。
  • 全球健康状况/生活质量至确定性恶化中位时间:Ven-Obi组82.1个月 vs Clb-Obi组65.1个月(HR 0.70;95%CI 0.51-0.97)。

临床怎么用

  • 长期生存和生活质量获益支持使用1年固定疗程维奈克拉-奥妥珠单抗治疗慢性淋巴细胞白血病。

局限性

  • 6年总生存率Ven-Obi组78.7% vs Clb-Obi组69.2%(HR 0.69;95%CI 0.48-1.01;P=.052),未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n = 216). Progression-free survival (PFS) was the primary end point. Key secondary end points included time-to-next-treatment (TTNT), rates of undetectable minimal residual disease (uMRD), overall survival (OS), and rates of adverse events. Patient reported outcomes of time until definitive deterioration (TUDD) in quality of life (QoL) were analyzed. At a median observation time of 76.4 months, PFS remained superior for Ven-Obi compared with Clb-Obi (median, 76.2 vs 36.4 months; hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.31-0.52; P < .0001). Likewise, TTNT was longer after Ven-Obi (6-year TTNT, 65.2% vs 37.1%; HR, 0.44; 95% CI, 0.33-0.58; P < .0001). In the Ven-Obi arm, presence of del(17p), unmutated immunoglobulin heavy-chain variable region, and lymph node size of ≥5 cm were independent prognostic factors for shorter PFS. The 6-year OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR, 0.69; 95% CI, 0.48-1.01; P = .052). A significantly longer TUDD in global health status/QoL was observed in the Ven-Obi than in the Clb-Obi arm (median, 82.1 vs 65.1 months; HR, 0.70; 95% CI, 0.51-0.97). Follow-up-adjusted second primary malignancies incidence rates were 2.3 and 1.4 per 1000 patient-months in the Ven-Obi and Clb-Obi arm, respectively. The sustained long-term survival and QoL benefits support the use of 1-year fixed-duration Ven-Obi in CLL. This trial was registered at www.ClinicalTrials.gov as #NCT02242942.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024. PMID: 39082668. doi:10.1182/blood.2024024631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。